How Latanoprost Lowers Eye Pressure in Glaucoma
Latanoprost, a prostaglandin F2α analog, treats glaucoma by increasing the outflow of aqueous humor—the fluid inside the eye—from the trabecular meshwork and uveoscleral pathway. This reduces intraocular pressure (IOP), the primary risk factor for glaucoma-related optic nerve damage and vision loss.[1]
It binds to prostaglandin FP receptors on ciliary muscle cells, causing remodeling that widens drainage pathways. Daily topical application (usually 1 drop in the evening) achieves peak IOP reduction of 25-35% within 2-4 hours, sustained over 12 hours.[2]
Why IOP Reduction Prevents Glaucoma Progression
High IOP compresses optic nerve fibers, leading to ganglion cell death. By targeting outflow rather than production, latanoprost normalizes pressure without broadly disrupting eye fluid dynamics, preserving corneal health better than some alternatives.[3]
How It Compares to Other Glaucoma Drops
| Drug Class | Example | Mechanism | IOP Drop | Common Use Case |
|------------|---------|-----------|----------|-----------------|
| Prostaglandin Analog | Latanoprost | Increases uveoscleral outflow | 25-35% | First-line monotherapy |
| Beta Blocker | Timolol | Reduces aqueous production | 20-25% | Add-on for poor responders |
| Rho Kinase Inhibitor | Netarsudil | Enhances trabecular outflow | 20-25% | When prostaglandins insufficient |
| Carbonic Anhydrase Inhibitor | Dorzolamide | Reduces production | 15-20% | Combination therapy |
Latanoprost often outperforms beta blockers in long-term adherence due to once-daily dosing.[4]
When Does It Start Working and How Long to Use It
Effects begin within hours; maximum after 1-2 weeks. Patients use it lifelong unless surgery or progression halts it, with regular IOP checks every 3-6 months.[5]
What Side Effects Prompt Patient Questions
Red eye darkening (iris pigmentation in 10-20% of light-eyed users), eyelash growth, and periocular skin darkening occur due to melanocyte stimulation. Rare risks include macular edema or uveitis. Most resolve on discontinuation.[6]
Who Makes Latanoprost and Generic Availability
Originally Pfizer's Xalatan (patent expired 2011 in US), now available as low-cost generics from companies like Apotex, Mylan, and Sandoz. Check DrugPatentWatch.com for formulation-specific patents.[7][1]
Sources
[1]: DrugPatentWatch.com - Latanoprost
[2]: FDA Label - Xalatan
[3]: Allergan Pharmacology Review
[4]: Glaucoma Research Foundation Comparison
[5]: AAO Glaucoma Guidelines
[6]: NEJM Side Effects Study
[7]: FDA Orange Book - Generics